⌛ Did you miss ProPicks’ 13% gains in May? Subscribe now & catch June’s top AI-picked stocks early.Unlock Stocks

Teva Pharma Industries Ltd ADR (TEVAN)

Mexico
Currency in MXN
Disclaimer
275.41
0.00(0.00%)
Delayed Data

TEVAN Comments

Post er the average of the new price targets is 19$ Nice. This will continue all the way to 30, 40$.
One day to ER of Q1
New price target of 17$ by Barclays analyst
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China April 11, 2024 8:30 AM AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile
1% on a Friday with 9.13M volume someone is buying.
simple story of debt reduction and value going up. revenue growth will set the pace will move up in the next 2-3 years to about 30-40$
long trend starting
hopefully ! Ive been w8ing for it for 3 y xD
11,40 will hold as celling or convert to floor :)?
looking good on pre-market. Wonder how USA downgrade might spoil the fun here
25 next year seems quite doable
Somebody know the consensus for Q2 today ?
first real report of new CEO... it will be interesting
OKE
so impressing strategy haha xD
😂😂😂
**achtung spoiler** 18th of may and the day after will be another slump. I bet new groth strategy will fail to encourage any whale
Why ? What is the info ? What will happen .
as you can see today a day b4 announced strategy presentation big volume and slide, insiders know that teva will fail again to encourage investors
fail after fail after fail and again and again
Patience is the name of the game .
for sure, just stating a fact
im out had it in 4 years an lost alot
what happened?
visit news section
humira biosimilar by teva and alvotech again backstopped...
Investing.com is a pathetic service . Once I found website with a news that investing requires pro-account to be available, it's always "something wrong" or notice that it's under spam control
at least 4% up today
LOL
heh :D not my fault its all bs US market's fault!
thanks for making this up today :p
results and guidance are reasonable, wonder how the market will get affected by them if anyhow.
Vero bad
Very
Accumulation keeps on going.
Teva ADR10.68+0.71(+7.12%) A brute today .)
exited for a while though - too many retard longs
back - let s go 12 this week
This is the company that cannot keep up with the demand of Adderol, causing pharmacies to be out for the past 4 months. If no-one has been buying their product, you would think future earning will take a hit. Guess we will just need to wait and see.
suppose to be valued around usd 25-usd30. its crazy they are sp undervalued....
...
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.